- Home
- RIGL vs NB Comparison
RIGL vs NB Comparison
Compare RIGL & NB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- NB
- Stock Information
- Founded
- RIGL 1996
- NB 1987
- Country
- RIGL United States
- NB United States
- Employees
- RIGL N/A
- NB N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- NB Metal Mining
- Sector
- RIGL Health Care
- NB Basic Materials
- Exchange
- RIGL Nasdaq
- NB Nasdaq
- Market Cap
- RIGL 335.5M
- NB 291.3M
- IPO Year
- RIGL 2000
- NB N/A
- Fundamental
- Price
- RIGL $37.96
- NB $5.28
- Analyst Decision
- RIGL Buy
- NB Strong Buy
- Analyst Count
- RIGL 5
- NB 2
- Target Price
- RIGL $38.20
- NB $4.50
- AVG Volume (30 Days)
- RIGL 761.5K
- NB 3.0M
- Earning Date
- RIGL 11-06-2025
- NB 09-11-2025
- Dividend Yield
- RIGL N/A
- NB N/A
- EPS Growth
- RIGL N/A
- NB N/A
- EPS
- RIGL 5.43
- NB N/A
- Revenue
- RIGL $267,921,000.00
- NB N/A
- Revenue This Year
- RIGL $59.93
- NB N/A
- Revenue Next Year
- RIGL N/A
- NB N/A
- P/E Ratio
- RIGL $6.99
- NB N/A
- Revenue Growth
- RIGL 105.62
- NB N/A
- 52 Week Low
- RIGL $12.76
- NB $1.27
- 52 Week High
- RIGL $43.72
- NB $5.33
- Technical
- Relative Strength Index (RSI)
- RIGL 56.17
- NB 68.76
- Support Level
- RIGL $35.56
- NB $4.16
- Resistance Level
- RIGL $42.65
- NB $4.63
- Average True Range (ATR)
- RIGL 2.19
- NB 0.38
- MACD
- RIGL -1.00
- NB 0.02
- Stochastic Oscillator
- RIGL 32.70
- NB 96.38
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.